NCT07124377Recruiting
Phenotypic Manifestations of Hereditary ATTR Amyloidosis
Phenotypic Manifestations of Hereditary ATTR Amyloidosis Val50Met Variant in a Non-endemic Area. Descriptive Study
Source: ClinicalTrials.gov · Last updated 2 Apr 2026
Brief summary (registry, in English)
This study focuses on hereditary transthyretin amyloidosis (ATTRv) with the Val50Met variant in a non endemic aerea
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 57 (estimated)
- First submitted
- 1 Aug 2025
- Start date
- 1 Sept 2024
- Primary completion date
- 30 Dec 2026
- Lead sponsor
- Hospital 9 de Julio de Las Breñas
- Diseases
- Amyloidosis
- NCT number
- NCT07124377
What you commit to
- Study type: Observational
- Planned participants: 57
- From 1 Sept 2024 to the primary completion date, 30 Dec 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Patients who refuse to participate.
Who the study is looking for
- All subjects between 20 and 70 years of age, carriers of the Val50Met variant
Age in the registry: 20 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hosptial Las Breñas Coordinator of this site? Confirm its status | Charata | Argentina | Recruiting |
| Hospital las Breñas 9 de Julio Coordinator of this site? Confirm its status | Charata | Argentina | Enrolling by invitation |
This page is information, not medical advice. Discuss any trial with your doctor.